TY - JOUR
T1 - Adaptive enterprise architecture for the digital healthcare industry
T2 - A digital platform for drug development
AU - Masuda, Yoshimasa
AU - Zimmermann, Alfred
AU - Viswanathan, Murlikrishna
AU - Bass, Matt
AU - Nakamura, Osamu
AU - Yamamoto, Shuichiro
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/2
Y1 - 2021/2
N2 - Enterprise architecture (EA) is useful for effectively structuring digital platforms with digital transformation in information societies. Moreover, digital platforms in the healthcare industry accelerate and increase the efficiency of drug discovery and development processes. However, there is the lack of knowledge concerning relationships between EA and digital platforms, in spite of the needs of it. In this paper, we investigated and analyzed the process of drug design and development within the healthcare industry, together with related work in using an enterprise architecture framework for the digital era named the Adaptive Integrated Digital Architecture Framework (AIDAF), specifically supporting the design of digital platforms there. Based on this analysis, we evaluate a method and propose a new reference architecture for promoting digital platforms in the healthcare industry, with future specific aspects of them making effective use of Artificial Intelligence (AI). The practical and theoretical contributions include: (1) Streamlined processes through digital platforms in organizations. (2) Informal knowledge supply and sharing among organizational members through digital platforms. (3) Efficiency and effectiveness in planning production and business for drug development. The findings indicate that EA with digital platforms using the AIDAF contribute to digital transformation with effectiveness for new drugs in the healthcare industry.
AB - Enterprise architecture (EA) is useful for effectively structuring digital platforms with digital transformation in information societies. Moreover, digital platforms in the healthcare industry accelerate and increase the efficiency of drug discovery and development processes. However, there is the lack of knowledge concerning relationships between EA and digital platforms, in spite of the needs of it. In this paper, we investigated and analyzed the process of drug design and development within the healthcare industry, together with related work in using an enterprise architecture framework for the digital era named the Adaptive Integrated Digital Architecture Framework (AIDAF), specifically supporting the design of digital platforms there. Based on this analysis, we evaluate a method and propose a new reference architecture for promoting digital platforms in the healthcare industry, with future specific aspects of them making effective use of Artificial Intelligence (AI). The practical and theoretical contributions include: (1) Streamlined processes through digital platforms in organizations. (2) Informal knowledge supply and sharing among organizational members through digital platforms. (3) Efficiency and effectiveness in planning production and business for drug development. The findings indicate that EA with digital platforms using the AIDAF contribute to digital transformation with effectiveness for new drugs in the healthcare industry.
KW - Artificial intelligence
KW - Cloud computing
KW - Digital healthcare
KW - Digital platform
KW - Digital transformation
KW - Enterprise architecture
KW - Knowledge management
UR - http://www.scopus.com/inward/record.url?scp=85100746036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100746036&partnerID=8YFLogxK
U2 - 10.3390/info12020067
DO - 10.3390/info12020067
M3 - Article
AN - SCOPUS:85100746036
SN - 2078-2489
VL - 12
SP - 1
EP - 26
JO - Information (Switzerland)
JF - Information (Switzerland)
IS - 2
M1 - 67
ER -